Lebertransplantation – wo stehen wir heute?

Schlüsselwörter

Lebertransplantation - Allokation - Organspende

Keywords

liver transplantation - allocation - organ donation

• Literatur

• 1 Andrews PA, Emery VC, Newstead C. Summary of the British Transplantation Society Guidelines for the Prevention and Management of CMV Disease After Solid Organ Transplantation. Transplantation 2011; 92: 1181-1187
• 2 Beckebaum S, Sotiropoulos GC, Klein CG et al. Predictive factors of outcome in patients transplanted for hepatitis B. Transplantation 2009; 87: 872-881
• 3 Bundesärztekammer. Richtlinien zur Organtransplantation gem. §16 Abs. 1 S.1 Nrn. 2 und 5 TPG. Dtsch Ärztebl 2013; 110: A241-A242
• 4 Cicinnati VR, Yu Z, Klein CG et al. Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients. Alimentary Pharmacol Ther 2007; 26: 1195-1208
• 5 Cornberg M, Protzer U, Petersen J et al. [Prophylaxis, diagnosis and therapy of hepatitis B virus infection – the German guideline]. Z Gastroenterol 2011; 49: 871-930
• 6 Erim Y, Beckmann M, Gerken G. [Psychosomatic aspects of living donor liver transplantation]. Der Chirurg 2010; 81: 820-825
• 7 Erim Y, Bottcher M, Dahmen U. Urinary ethyl glucuronide testing detects alcohol consumption in alcoholic liver disease patients awaiting liver transplantation. Liver Transplant 2007; 13: 757-761
• 8 Feng S, Goodrich NP, Bragg-Gresham JL et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006; 6: 783-790
• 9 Fischer L, Klempnauer J, Beckebaum S et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation – PROTECT. Am J Transplant 2012; 12: 1855-1865
• 10 Garg V, van Heeswijk R, Lee JE. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20-27
• 11 Herrero JI. Screening of de novo tumors after liver transplantation. J Gastroenterol 2012; 27: 1011-1016
• 12 Iacob S, Cicinnati VR, Beckebaum S. Current immunosuppressive approaches in liver transplantation. Panminerva Med 2009; 51: 215-225
• 13 Kabar I, Cicinnati VR, Beckebaum S. Introducing paclitaxel-eluting balloons as a new treatment option of biliary-enteric anastomotic stricture after liver transplantation. Transplantation 2012; 94: e4-5
• 14 Kaido T, Uemoto S. Does living donation have advantages over deceased donation in liver transplantation?. J Gastroenterol Hepatol 2010; 25: 1598-1603
• 15 Kamdar KY, Rooney CM, Heslop HE. Posttransplant lymphoproliferative disease following liver transplantation. Curr Opin Organ Transplant 2011; 16: 274-280
• 16 Kinner S, Dechene A, Ladd SC et al. Comparison of different MRCP techniques for the depiction of biliary complications after liver transplantation. Europ Radiol 2010; 20: 1749-1756
• 17 Kinner S, Dechene A, Paul A et al. Detection of biliary stenoses in patients after liver transplantation. Europ J Radiol 2011; 80: e20-28
• 18 Mathurin P, Moreno C, Samuel D et al. Early liver transplantation for severe alcoholic hepatitis. New Engl J Med 2011; 365: 1790-800
• 19 Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New Engl J Med 1996; 334: 693-699
• 20 NIH. National Institutes of Health Consensus Development Conference on Liver Transplantation. Hepatology 1984; 4 (Suppl. 01) 1S-110S
• 21 Neil DA, Hubscher SG. Current views on rejection pathology in liver transplantation. Transplant Int 2010; 23: 971-983
• 22 Neumann UP, Biermer M, Eurich D. Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy. J Hepatol 2010; 52: 951-952
• 23 Saner FH, Cicinnati VR, Sotiropoulos G. Strategies to prevent or reduce acute and chronic kidney injury in liver transplantation. Liver Int 2012; 32: 179-188
• 24 Sarrazin C, Berg T, Ross RS et al. [Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. Z Gastroenterol 2010; 48: 289-351
• 25 Schaubel DE, Sima CS, Goodrich NP. The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant 2008; 8: 419-425
• 26 Schrem H, Barg-Hock H, Strassburg CP. Aftercare for patients with transplanted organs. Dtsch Arztebl Int 2009; 106: 148-156
• 27 Toso C, Mentha G, Kneteman NM. The place of downstaging for hepatocellular carcinoma. J Hepatol 2010; 52: 930-936
• 28 Washington K. Update on post-liver transplantation infections, malignancies, and surgical complications. Advanc Anatom Pathol 2005; 12: 221-226
• 29 Weismuller TJ, Fikatas P, Schmidt J et al. Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany. Transplant Int 2011; 24: 91-99
• 30 Welker MW, Bechstein WO, Zeuzem S. Recurrent hepatocellular carcinoma after liver transplantation. Transplant Int 2013; 26: 109-118
• 31 Wibaux C, Legroux-Gerot I, Dharancy S et al. Assessing bone status in patients awaiting liver transplantation. Joint Bone Spine 2011; 78: 387-391
• 32 Wiesner R, Edwards E, Freeman R et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-96
• 33 Zoepf T, Maldonado de Dechene EJ, Dechene A et al. Optimized endoscopic treatment of ischemic-type biliary lesions after liver transplantation. Gastroint Endosc 2012; 76: 556-563
• 34 Zoepf T, Maldonado-Lopez EJ, Hilgard P et al. Balloon dilatation vs. balloon dilatation plus bile duct endoprostheses for treatment of anastomotic biliary strictures after liver transplantation. Liver Transplant 2006; 12: 88-94